Literature DB >> 20577780

IL-8 is a mediator of NF-κB induced invasion by gliomas.

Baisakhi Raychaudhuri1, Michael A Vogelbaum.   

Abstract

Glioblastoma (GBM) is the most common and deadly form of primary brain tumor with a median survival of eleven months, despite use of extensive chemotherapy, radiotherapy and surgery. We have previously shown that nuclear factor-kappa B (NF-κB) is aberrantly expressed in GBM tumors and primary cell lines derived from tumor tissue. Here we show that IL-8, a chemokine is also aberrantly expressed by GBM cell lines and expression of IL-8 is in large part, attributable to the aberrant activation of NF-κB. We hypothesized that invasiveness of GBM cells is driven at least in part by aberrantly expressed IL-8. In support of the hypothesis we found that treatment of glioma cells with an IL-8 neutralizing antibody markedly decreased their invasiveness compared to cells treated with control IgG or left untreated. Furthermore, downregulation of IL-8 protein production with use of IL-8 targeted siRNA also resulted in decreased invasion in matrigel. We next investigated the presence of IL-8 receptors by FACS analysis and found that GBM cells (U87, U251, D54 and LN229) only express CXCR1 but not CXCR2. Treatment of U87 cells with a blocking CXCR1 antibody reduced their invasion through matrigel. Finally, we found that addition of exogenous IL-8, following downregulation of NF-κB which results in loss of endogenous IL-8 production, incompletely restored tumor cell invasion. Our data indicate that IL-8 is necessary but not solely responsible for glioma cell invasion and mediates its effect in an autocrine manner.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20577780     DOI: 10.1007/s11060-010-0261-2

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  34 in total

1.  Interleukin 8 in human hepatocellular carcinoma correlates with cancer cell invasion of vessels but not with tumor angiogenesis.

Authors:  Fumitake Kubo; Shinichi Ueno; Kiyokazu Hiwatashi; Masahiko Sakoda; Koichi Kawaida; Kensuke Nuruki; Takashi Aikou
Journal:  Ann Surg Oncol       Date:  2005-08-09       Impact factor: 5.344

Review 2.  The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis.

Authors:  Daniel J Brat; Anita C Bellail; Erwin G Van Meir
Journal:  Neuro Oncol       Date:  2005-04       Impact factor: 12.300

3.  Expression of interleukin 8 and its receptors in human colon carcinoma cells with different metastatic potentials.

Authors:  A Li; M L Varney; R K Singh
Journal:  Clin Cancer Res       Date:  2001-10       Impact factor: 12.531

Review 4.  Multiple control of interleukin-8 gene expression.

Authors:  Elke Hoffmann; Oliver Dittrich-Breiholz; Helmut Holtmann; Michael Kracht
Journal:  J Leukoc Biol       Date:  2002-11       Impact factor: 4.962

Review 5.  Interleukin-8 and human cancer biology.

Authors:  K Xie
Journal:  Cytokine Growth Factor Rev       Date:  2001-12       Impact factor: 7.638

6.  CXCR4 regulates growth of both primary and metastatic breast cancer.

Authors:  Matthew C P Smith; Kathryn E Luker; Joel R Garbow; Julie L Prior; Erin Jackson; David Piwnica-Worms; Gary D Luker
Journal:  Cancer Res       Date:  2004-12-01       Impact factor: 12.701

7.  Structure and functional expression of a human interleukin-8 receptor.

Authors:  W E Holmes; J Lee; W J Kuang; G C Rice; W I Wood
Journal:  Science       Date:  1991-09-13       Impact factor: 47.728

8.  Growth inhibition of human glioma cells modulated by retrovirus gene transfection with antisense IL-8.

Authors:  R Yamanaka; R Tanaka; S Yoshida; T Saitoh; K Fujita
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

9.  Interleukin-8 as a macrophage-derived mediator of angiogenesis.

Authors:  A E Koch; P J Polverini; S L Kunkel; L A Harlow; L A DiPietro; V M Elner; S G Elner; R M Strieter
Journal:  Science       Date:  1992-12-11       Impact factor: 47.728

10.  Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis.

Authors:  Jan-Hendrik Egberts; Vera Cloosters; Andreas Noack; Bodo Schniewind; Lutz Thon; Stefanie Klose; Bastian Kettler; Corinna von Forstner; Christian Kneitz; Jürgen Tepel; Dieter Adam; Harald Wajant; Holger Kalthoff; Anna Trauzold
Journal:  Cancer Res       Date:  2008-03-01       Impact factor: 12.701

View more
  42 in total

Review 1.  Chemoattractant receptors as pharmacological targets for elimination of glioma stem-like cells.

Authors:  Xiao-hong Yao; Ying Liu; Keqiang Chen; Wanghua Gong; Ming-yong Liu; Xiu-wu Bian; Ji Ming Wang
Journal:  Int Immunopharmacol       Date:  2011-09-17       Impact factor: 4.932

2.  Autocrine IL-8 promotes F-actin polymerization and mediate mesenchymal transition via ELMO1-NF-κB-Snail signaling in glioma.

Authors:  Baogang Zhang; Lihong Shi; Shijun Lu; Xiuning Sun; Yuqing Liu; Hongli Li; Xuejian Wang; Chunzhen Zhao; Heng Zhang; Ying Wang
Journal:  Cancer Biol Ther       Date:  2015-04-14       Impact factor: 4.742

3.  Glioblastoma stem cells are regulated by interleukin-8 signaling in a tumoral perivascular niche.

Authors:  David W Infanger; YouJin Cho; Brina S Lopez; Sunish Mohanan; S Chris Liu; Demirkan Gursel; John A Boockvar; Claudia Fischbach
Journal:  Cancer Res       Date:  2013-10-11       Impact factor: 12.701

4.  Evaluation of radiation-related invasion in primary patient-derived glioma cells and validation with established cell lines: impact of different radiation qualities with differing LET.

Authors:  M Wank; D Schilling; J Reindl; B Meyer; J Gempt; S Motov; F Alexander; J J Wilkens; J Schlegel; T E Schmid; S E Combs
Journal:  J Neurooncol       Date:  2018-06-08       Impact factor: 4.130

Review 5.  Novel siRNA delivery strategy: a new "strand" in CNS translational medicine?

Authors:  Lisa Gherardini; Giuseppe Bardi; Mariangela Gennaro; Tommaso Pizzorusso
Journal:  Cell Mol Life Sci       Date:  2013-03-19       Impact factor: 9.261

Review 6.  Interleukins in glioblastoma pathophysiology: implications for therapy.

Authors:  Y T Yeung; K L McDonald; T Grewal; L Munoz
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

7.  Role of GPER1, EGFR and CXCR1 in differentiating between malignant follicular thyroid carcinoma and benign follicular thyroid adenoma.

Authors:  Le Zhao; Xiao-Yun Zhu; Rong Jiang; Man Xu; Ni Wang; George G Chen; Zhi-Min Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

8.  Mutant tristetraprolin: a potent inhibitor of malignant glioma cell growth.

Authors:  Esther A Suswam; John J Shacka; Kiera Walker; Liang Lu; Xuelin Li; Ying Si; Xiaowen Zhang; Lei Zheng; L Burt Nabors; Heping Cao; Peter H King
Journal:  J Neurooncol       Date:  2013-03-25       Impact factor: 4.130

9.  High expression of GPER1, EGFR and CXCR1 is associated with lymph node metastasis in papillary thyroid carcinoma.

Authors:  Cui Tang; Lei Yang; Ni Wang; Li Li; Man Xu; George G Chen; Zhi-Min Liu
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

10.  Glioma vessel abnormality quantification using time-of-flight MR angiography.

Authors:  Maddalena Strumia; Wilfried Reichardt; Ori Staszewski; Dieter Henrik Heiland; Astrid Weyerbrock; Irina Mader; Michael Bock
Journal:  MAGMA       Date:  2016-04-20       Impact factor: 2.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.